Diseases / Pulmonary Fibrosis
Pulmonary Fibrosis
DiseasePulmonary fibrosis is a chronic interstitial lung disease characterized by progressive scarring of lung tissue, leading to reduced lung compliance, impaired gas exchange, and progressive dyspnea.
- Trials
- 331
- Recruiting
- 55
- Completed
- 140
- With results
- 44
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | 2 | — | 1 | — | — | 2 | — | 5 |
| Phase 1 | 4 | — | — | 1 | 16 | 2 | — | — | 2 | — | 25 |
| Phase 1/2 | 2 | 1 | — | — | 3 | 1 | — | — | 2 | — | 9 |
| Phase 2 | 11 | — | 2 | 3 | 28 | 12 | 4 | 1 | 4 | — | 65 |
| Phase 2/3 | 1 | — | — | 1 | 5 | 1 | — | — | 3 | — | 11 |
| Phase 3 | 2 | 1 | — | 2 | 11 | 7 | — | — | 2 | — | 25 |
| Phase 4 | — | 1 | — | — | 5 | — | — | — | 5 | — | 11 |
| Not applicable | 11 | 4 | 1 | 1 | 27 | 3 | — | — | 12 | — | 59 |
| Unknown | 24 | 6 | 2 | 10 | 45 | 3 | 1 | — | 28 | 2 | 121 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Pulmonary Fibrosis | 5 | 25 | 9 | 65 | 11 | 25 | 11 | 59 | 121 | 331 |
| Lung Diseases, Interstitial | 2 | 2 | 1 | 18 | 2 | 5 | 4 | 21 | 37 | 92 |
| Idiopathic Pulmonary Fibrosis | 1 | 10 | 1 | 31 | 3 | 13 | — | 8 | 21 | 88 |
| Lung Diseases | — | 5 | 1 | 9 | 2 | 5 | — | 3 | 10 | 35 |
| Pulmonary Disease, Chronic Obstructive | 1 | 1 | 1 | 1 | — | — | 1 | 13 | 11 | 29 |
| COVID-19 | — | 1 | 2 | 4 | 1 | 1 | 2 | 4 | 7 | 22 |
| Fibrosis | — | 3 | — | 10 | — | 3 | 1 | 2 | 2 | 21 |
| Hypertension, Pulmonary | 1 | — | 1 | 8 | 1 | 2 | 2 | 2 | 4 | 21 |
| Sarcoidosis | — | — | 1 | 2 | — | 1 | — | 4 | 9 | 17 |
| Emphysema | 1 | 1 | 1 | — | — | — | — | 6 | 5 | 14 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Heart, Lung, and Blood Institute (NHLBI) | 12 | 0 |
| 2 | Boehringer Ingelheim | 9 | 2 |
| 3 | Bristol-Myers Squibb | 6 | 3 |
| 4 | National Jewish Health | 6 | 0 |
| 5 | National Human Genome Research Institute (NHGRI) | 5 | 0 |
| 6 | Peking Union Medical College Hospital | 5 | 0 |
| 7 | Assistance Publique - Hôpitaux de Paris | 4 | 2 |
| 8 | Erasmus Medical Center | 4 | 0 |
| 9 | InterMune | 4 | 3 |
| 10 | Kyntra Bio | 4 | 2 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | pirfenidone | 15 |
| 2 | nintedanib | 11 |
| 3 | Acetylcysteine | 4 |
| 4 | Blood Specimen Collection | 4 |
| 5 | Cyclophosphamide | 4 |
| 6 | Exercise | 4 |
| 7 | Oxygen | 4 |
| 8 | pamrevlumab | 4 |
| 9 | Rituximab | 4 |
| 10 | Sildenafil Citrate | 4 |
Evidence
- Results reported
- 31.4%44 of 140 completed
- Published
- 15.7%22 of 140 completed
- Primary endpoint met
- 35.6%16 of 45 analyses
- Median months to report
- 14
Documents disclosed
Trial profile
- Median enrollment
- 80
- Median duration
- 34months
- Countries
- 60
- Study sites
- 3323
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 20
- Phase 1
- 32
- Phase 1/2
- 27
- Phase 2
- 50
- Phase 2/3
- 60
- Phase 3
- 202
- Phase 4
- 60
- Not applicable
- 51
- Unknown
- 150
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Los Angeles | United States | 28 |
| 2 | Nashville | United States | 28 |
| 3 | Boston | United States | 25 |
| 4 | Chicago | United States | 24 |
| 5 | Birmingham | United States | 22 |
| 6 | New York | United States | 21 |
| 7 | Charleston | United States | 20 |
| 8 | Dallas | United States | 20 |
| 9 | Philadelphia | United States | 20 |
| 10 | Beijing | China | 19 |
Terminations
- Terminated
- 30
- Withdrawn
- 5
- Suspended
- 1
- Stopped for recruitment
- 1.8%6 of 331 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05676112 Withdrawn | Withdrawn | Company decision | 2026-09-30 |
| NCT06399094 Terminated | Terminated | Recruitment issue | 2025-08-30 |
| NCT06097260 Terminated | Terminated | DSMB recommendation | 2025-04-04 |
| NCT04638517 Terminated | Terminated | Data Safety Monitoring Board recommended cessation due to futility | 2025-01-16 |
| NCT05032066 Terminated | Terminated | The trial was terminated due to not meeting primary or key secondary endpoints. | 2025-01-02 |
| NCT05387239 Suspended | Suspended | Sponsor request | 2024-12-31 |
| NCT04837131 Terminated | Terminated | Low enrollment | 2024-02-23 |
| NCT04419558 Terminated | Terminated | Sponsor Decision | 2023-09-04 |
| NCT03955146 Terminated | Terminated | Study did not meet its primary endpoint. | 2023-08-28 |
| NCT03267108 Terminated | Terminated | The trial did not meet its primary endpoint, hence was terminated due to futility. | 2023-06-30 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Pulmonary Fibrosis trials on ClinicalTrials.gov →